NOD2/CARD15 gene polymorphism in patients with inflammatory bowel disease: Is Hungary different?

Carsten Büning, Tomas Molnar, Ferenc Nagy, Janos Lonovics, Renita Weltrich, Bettina Bochow, Janine Genschel, Hartmut Schmidt, Herbert Lochs

Abstract

AIM: To analyse the impact of NOD2/CARD15 mutations on the clinical course of Crohn’s disease patients from an eastern European country (Hungary).

METHODS: We investigated the prevalence of the three common NOD2/CARD15 mutations (Arg702Trp, Gly908Arg, 1007finsC) in 148 patients with Crohn’s disease, 128 patients with ulcerative colitis and 208 controls recruited from the University of Szeged, Hungary. In patients with Crohn’s disease, the prevalence of NOD2/CARD15 mutations was correlated to the demographical and clinical parameters.

RESULTS: In total, 32.4% of Crohn’s disease patients carried at least one mutant allele within NOD2/CARD15 compared to 13.2% of patients with ulcerative colitis ($P = 0.0002$) and to 11.5% of controls ($P<0.0001$). In Crohn’s disease patients, the allele frequencies for Arg702Trp, Gly908Arg and 1007finsC were 7.1%, 3.0% and 10.8% respectively. Interestingly, only the 1007finsC mutation was associated with a distinct clinical phenotype. The patients positive for the 1007finsC mutation suffered more frequently from stenotic disease ($P = 0.008$). Furthermore, 51.9% of patients positive for the 1007finsC mutation underwent a surgical resection within the ileum compared to only 17.4% of patients without the 1007finsC mutation ($P = 0.001$). With respect to the other two mutations (Arg702Trp and Gly908Arg), no associations were found with all investigated clinical parameters.

CONCLUSION: NOD2/CARD15 mutations are frequently found in Crohn’s disease patients from Hungary. The 1007finsC mutation is associated with stenotic disease behaviour and frequent ileal resections.

INTRODUCTION

There is a strong support for the genetic influence on the pathophysiology of inflammatory bowel diseases (Crohn’s disease and ulcerative colitis). Recent studies reported an association between Crohn’s disease and mutations in the NOD2/CARD15 gene located on chromosome 16q12 (IBD1)[1-3]. NOD2/CARD15 acts as an intracellular receptor in monocytes for bacterial components triggering activation of NFκB thus leading to subsequent activation of the inflammatory response. These findings fit perfectly in the current working hypothesis that a dysregulated immune response towards antigens of fecal bacteria in a genetically susceptible host is the main pathogenetic feature in Crohn’s disease.

Within the NOD2/CARD15 gene, three mutations have been identified to be associated with Crohn’s disease: two missense mutations (Arg702Trp in exon 4 and Gly908Arg in exon 8) and an insertion mutation of a C in exon 11 (1007finsC), the latter resulting in a truncated NOD2/CARD15 protein. Numerous studies have been performed mostly in northern America and western Europe to determine the frequency of NOD2/CARD15 mutations in inflammatory bowel disease populations. In Crohn’s disease patients from western Europe or northern America, allele frequencies ranged from 9.1-12.9%, 3.3-6.0% and 6.6-16.0% for Arg702Trp, Gly908Arg, 1007finsC, respectively[4]. Interestingly, a recent study in Finnish IBD patients reported lower allele frequencies for all of the three NOD2/CARD15 mutations in Crohn’s disease patients compared to the above-mentioned studies and furthermore similar frequencies in patients with ulcerative colitis[5]. Additionally, in Asian IBD populations NOD2/CARD15 mutations could not be detected at all[6,7]. This raises the need for more studies in different IBD populations. Up to now, no data is available on the occurrence of NOD2/CARD15 mutations in countries located between western Europe and Asia, e.g., eastern Europe. The first aim of our study was therefore to analyse for the first time the frequency of NOD2/CARD15 mutations in an eastern European country (Hungary). Patients with inflammatory bowel disease were recruited from the University of Szeged. Szeged is one of the largest cities in Hungary with a population of approximately 186 000. Located along the Tisza river and close to the border of Romania, Szeged is the cultural and economic center of South-Eastern Hungary.

With respect to the occurrence of inflammatory bowel disease in Hungary, a recent report from Lakatos and colleagues reported an increase of both Crohn’s disease and ulcerative colitis in a province of Western Hungary from 1977 to 2001. In ulcerative colitis, the incidence increased from 1.66 to 11.01 and from 0.41 to 4.68 in Crohn’s disease per 100.00 persons. Prevalence rates were reported to be 142.6 and 52.9 per 100.00 persons for ulcerative colitis and Crohn’s disease respectively[8]. The incidence and prevalence rates of inflammatory bowel disease in Hungary are comparable to western European countries[9].

Interestingly, observations in Hungary suggest differences in disease prevalence among the Roma (Gipsy) minority compared to the Caucasian population. Concentrated in some

© 2005 The WJG Press and Elsevier Inc. All rights reserved.

Key words: Crohn’s disease; NOD2/CARD15 gene; Mutation

Büning C, Molnar T, Nagy F, Lonovics J, Weltrich R, Bochow B, Genschel J, Schmidt H, Lochs H. NOD2/CARD15 gene polymorphism in patients with inflammatory bowel disease: Is Hungary different? World J Gastroenterol 2005; 11(3): 407-411 http://www.wjgnet.com/1007-9327/11/407.asp
Hungarian regions, the incidence of IBD within the Roma minority is half compared to the rest of the population living in these areas\cite{10}.

Crohn’s disease shares a number of various phenotypes with differences in age at onset of disease, disease location and behaviour\cite{11}. With respect to NOD2/CARD15 mutations, investigations have been performed to analyse the clinical impact of these mutations on Crohn’s disease. Associations with ileal involvement\cite{12-15}, younger age at diagnosis\cite{16}, and fibrostenotic disease behaviour\cite{17,18} have been described. However, only some of these associations were replicated by other investigators. In our recent observations in a large German cohort, we found an association with ileocolic resections and neoterminal reoperations\cite{19}. The second aim of our study was, therefore, to observe the genotype-phenotype correlation to answer the question whether a certain phenotype was associated with NOD2/CARD15 mutations.

In this study, we investigated the frequency of the three common NOD2/CARD15 mutations in 276 patients with inflammatory bowel disease and in 208 controls from Hungary. Furthermore, a detailed phenotype genotype analysis was performed to elucidate the clinical impact of NOD2/CARD15 mutations on the course of Crohn’s disease.

MATERIALS AND METHODS

Patients

We included 148 patients with Crohn’s disease in the study, who were diagnosed according to clinical, endoscopic, radiological and histological findings\cite{20}. All patients were recruited from the 1st Department of Medicine, Faculty of Medicine, University of Szeged, Hungary. The study was approved by the Ethical Committee of the department. Informed consent was obtained from each participant.

Among the 148 patients, 138 were Caucasians and 10 were from the Roma minority (Gypsy). Clinical data were obtained from the patients clinical charts at the 1st Department of Medicine, University of Szeged, Hungary. Genotyping, statistical analysis and drafting of the manuscript were performed at the Charité, Berlin.

The following data of patients with Crohn’s disease was collected: age, age at diagnosis, gender, familial or spontaneous disease (familial disease was considered if one first- or second-degree relative had IBD), smoking habits (current smoking/never smoked), disease localisation, disease behaviour, perianal disease, extraintestinal manifestations (arthritis, affections of eyes or skin, primary sclerosing cholangitis), type and location of surgery. Disease localisation was defined as the maximum extent of digestive tract involvement at the latest followup. Information was obtained through the ICycler IQ real-time PCR detection system and the appropriate software (BioRad, München, Germany). The analysis was confirmed by sequencing in both directions.

Statistical analysis

Comparison of the frequency of NOD2/CARD15 mutations was made between patients and controls, and the analysis of association with the phenotype was performed by $\chi^2$ test or Fisher’s exact test when appropriate. For analysis of age and age at disease diagnosis, Wilcoxon-U-Mann-Whitney test was applied.

Polymerase chain reaction and sequencing

Genomic DNA from index patients and controls was prepared using commercially available extraction columns (QIAamp Blood Kit, QIAGEN, Hilden, Germany).

Exon 11 of the NOD2 gene was amplified using the following primers: forward primer 5’-ggg aca ggt ggg ctt cag ta-3’, reverse primer 5’-cca tgt ttc ttc tct ccc gtc ac-3’. The annealing temperature was 62 °C. DNA sequencing of the amplified exon was performed by cycle sequencing with fluorescent dye terminators. Analysis was performed using an ABI 310 automatic sequencer (Applied Biosystems, Weiterstadt, Germany). The analysis was confirmed by sequencing in both directions.

SNP genotyping

Genotyping of the three most common NOD2/CARD15 SNPs (Arg702Trp, Gly908Arg, 1007insC) was performed using the fluorogenic 5’-nuclease assay with the primers and probes listed in Table 1.

| SNP       | Primers                       | Probes                        | Annealing |
|-----------|-------------------------------|-------------------------------|-----------|
| Arg702Trp | GTCGAGATGGTCCTGGAGCACGAGG     | FAM-CCCCTCCTCGGGGCCCCAGGC-TAMRA | 64.5 °C   |
|           | TACGACTGACTGCTGTGGCAGGGAG     | TET-CCTTCCTGGGCCCCGAGC-TAMRA  |           |
| Gly908Arg | ACTCACTGACACTGCTGTCGAGGAG     | FAM-TTTTACATCTGCGGCAACAGGAGTTG-TAMRA |           |
|           | AGGCCCTGACAGGCTCTGAGG         | TET-TTCAGATTTCCTGGCCACAGGAGTTG-TAMRA |           |
| 3020insC | GCCCAAATACTGACACTGACTACCTAG   | FAM-CCCTCCCTGGACGCGGGCTGGAAT-TAMRA | 62.5 °C   |
|           | CTACGACTGACTGCTGGGAG         | TET-CCTCCCCGAGCGGGCTGGAA-TAMRA  |           |

Table 1: Primers and Probes used in genotyping of NOD2/CARD15 genetic variants

The following extraintestinal manifestations were determined: arthritis, presence of primary sclerosing cholangitis (PSC) diagnosed through endoscopic cholangiography, affections of skin (e.g., presence of erythema nodosum or pyoderma gangrenosum) or eye (e.g., presence of episcleritis or anterior uveitis).

Genotyping for the three NOD2/CARD15 mutations was also performed in 128 patients with ulcerative colitis (m:157±71; age 16–79 years). These patients were also recruited from the First Department of Medicine, University of Szeged, Hungary. A total of 208 unrelated Hungarian healthy individuals served as controls (m:196±12; age 18–86 years).

Table 1: Primers and Probes used in genotyping of NOD2/CARD15 genetic variants

Comparison of the frequency of NOD2/CARD15 mutations was performed using $\chi^2$ test or Fisher’s exact test when appropriate. For analysis of age and age at disease diagnosis, Wilcoxon-U-Mann-Whitney test was applied. $P$ values less than 0.05 were considered statistically significant. The data was analysed using SPSS/PC+V10.01 software (SPSS, Chicago, USA).
RESULTS

Distribution of NOD2/CARD15 mutations in Hungarian IBD patients

First, we investigated the frequency of the three NOD2/CARD15 mutations in 276 patients with inflammatory bowel disease and compared them to 208 controls. Genotypes and allele frequencies are shown in Table 2. A total of 32.4% of Crohn’s disease patients carried at least one mutant allele within NOD2/CARD15 compared to 13.2% of patients with ulcerative colitis (P = 0.0002) and to 11.5% of controls (P=0.0001). The difference between patients with ulcerative colitis and controls was not statistically significant.

With respect to the 1007finsC mutation, 18.2% of Crohn’s disease patients were either heterozygous or homozygous compared to 4.7% of patients with ulcerative colitis (P = 0.001) and 4.3% of controls (P=0.0001). Although the other two mutations (Arg702Trp and Gly908Arg) were found in clearly higher frequencies in patients with Crohn’s disease compared to patients with ulcerative colitis and controls, not all comparisons reached statistical significance (Table 2). Among the 10 Roma (Gipsy) patients, only one patient carried a mutation within NOD2/CARD15 (1007finsC).

Genotype phenotype analysis

In the next step a detailed genotype phenotype analysis was performed in the 148 patients with Crohn’s disease. The percentages of Crohn’s disease patients positive or negative for each individual NOD2/CARD15 mutation were correlated to demographic data, disease localisation, disease behaviour, extraintestinal manifestations and surgical interventions (Table 3).

The 1007finsC mutation was negatively correlated to inflammatory disease behaviour (P = 0.001) and positively associated with stenotic disease behaviour (P = 0.008). The frequency of ileal involvement was higher in patients positive for the 1007finsC mutation (66.7%) compared to patients negative for the 1007finsC mutation (51.2%), but this difference was not significant (P = 0.20).

We also analysed the correlation of frequency and location of surgical resections to the NOD2/CARD15 genotype. More than half of the patients positive for the 1007finsC mutation (51.9%) underwent a surgical resection of the ileum, while only 17.4% of patients without mutation were operated (P = 0.001). These findings could not be explained by different disease durations or disease locations in the two groups (Table 3). Furthermore, the association of the 1007finsC mutation with surgical interventions was specific for the ileal region since no differences were found when frequencies of large bowel resections were analysed (Table 3).

Table 3 Clinical characteristics of Crohn’s disease patients

| Genotype       | 1007finsC (+) | 1007finsC (-) |
|----------------|--------------|---------------|
| Total Number   | 27           | 121           |
| Male: female   | 11:16        | 57:64         |
| Age at diagnosis (yr) | 13-46      | 12-65         |
| mean±SD        | 25.9±8.0     | 30.1±12.8     |
| Race, n (%)    |              |               |
| Caucasian      | 26 (96.3)    | 112 (92.6)    |
| Roma (Gipsy)   | 1 (3.7)      | 9 (7.4)       |
| Disease Duration (yr) | 9.1±6.9   | 8.5±8.1       |
| Familial Crohn’s disease, n (%) | 1 (3.7)   | 9 (7.4)       |
| Sporadic Crohn’s disease, n (%) | 26 (96.3) | 112 (92.6)    |
| Smoking Habits, n (%) |              |               |
| Never          | 15 (55.6)    | 69 (57.0)     |
| Current        | 11 (40.7)    | 48 (39.7)     |
| Ex-Smoker      | 1 (3.7)      | 4 (3.3)       |
| Localisation, n (%) |        |               |
| Upper Gl       | 3 (11.1)     | 4 (3.3)       |
| Ileum          | 18 (66.7)    | 62 (51.2)     |
| Colon          | 20 (74.1)    | 103 (85.1)    |
| Perianal Disease | 7 (26.0)   | 5 (28.9)      |
| Behaviour, n (%) |              |               |
| Inflammatory   | 2 (7.4)³     | 47 (38.8)     |
| Strictureing    | 17 (63.0)²   | 40 (33.0)     |
| Penetrating     | 12 (44.4)    | 46 (38.0)     |
| Surgery, n (%) |              |               |
| Ileal resections | 14 (51.9)³ | 21 (17.4)     |
| Colonic resections | 7 (26.0)   | 21 (17.4)     |
| Fistulae        | 1 (3.7)      | 3 (2.5)       |
| Extraintestinal manifestation, n (%) |        |               |
| Arthritis       | 3 (11.1)     | 17 (14.0)     |
| Primary scleroscholangitis | 0 | 2 (1.7) |
| Skin            | 0            | 7 (5.8)       |
| Eye             | 0            | 1 (0.8)       |

¹Inflammatory disease behaviour was negatively correlated to the 1007finsC mutation (P = 0.001, Fisher’s exact test).
²Stenotic disease behaviour was significantly associated with the 1007finsC mutation (P = 0.008, Fisher’s exact test).
³Ileal resections were performed significantly more often in patients positive for the 1007finsC mutation (P = 0.001, Fisher’s exact test). No other significant differences were found.

Table 2 NOD2/CARD15 genotypes and allele frequencies in Hungarian IBD patients

| Patients | Genotypes | -/- n (%) | +/+ n (%) | +/+ n (%) | Allele frequency (%) | P value¹ |
|----------|-----------|-----------|-----------|-----------|----------------------|----------|
| Arg702Trp | CD        | 129 (87.2) | 17 (11.5) | 2 (1.4)   | 7.1                  | 0.01³    |
|          | UC        | 120 (93.8) | 8 (6.3)   | 0         | 3.1                  | 0.07²    |
| Controls | 197 (94.7) | 11 (5.3)   | 0         | 3.0       | 0.10³                |          |
| Gly908Arg | CD        | 139 (93.9) | 9 (6.1)   | 0         | 1.6                  | 0.27²    |
|          | UC        | 124 (96.9) | 4 (3.1)   | 0         | 0.2                  |          |
| Controls | 203 (97.4) | 5 (2.6)    | 0         | 3.0       | n.s.³                |          |
| 1007finsC | CD        | 122 (82.4) | 22 (14.9) | 5 (3.4)   | 10.8                 | <0.0001³|
|          | UC        | 122 (95.3) | 6 (4.7)   | 0         | 2.3                  | 0.001²   |
| Controls | 199 (95.7) | 9 (4.3)    | 0         | 2.2       | n.s.³                |          |

Crohn’s disease (CD, n = 148), ulcerative colitis (UC, n = 128) and controls (n=208); Genotypes: -/- : homozygous wild-type, +/- : heterozygous mutant, +/+ : homozygous mutant; Absolute numbers (percentages) of individuals negative (-/-), heterozygous (+/-), homozygous (+/+).
With respect to all other clinical and demographic data, including age at onset of the disease, disease duration, familial or sporadic disease, smoking behaviours or extraintestinal manifestations, no significant differences were found with respect to the 1007finsC genotype within NOD2/CARD15 (Table 3). Additionally, genotype phenotype investigations performed with respect to the other two NOD2/CARD15 mutations (Arg702Trp and Gly908Arg) did not reveal any significant findings (data not shown).

**DISCUSSION**

This is the first study to investigate the frequency of NOD2/CARD15 mutations in an eastern European IBD population (Hungary). A total of 32.4% of Crohn’s disease patients carried at least one mutant allele of the three investigated NOD2/CARD15 mutations. This is in agreement with the reported frequency of NOD2/CARD15 mutations in western European Crohn’s disease populations. In contrast, lower frequencies were reported in Finnish IBD patients and NOD2/CARD15 mutations have not been found at all in Asian patients.

We observed a significant association between the 1007finsC mutation and stenotic disease behaviour. Similar findings have been reported by other investigators. In our study, this stenotic disease behaviour seemed to lead to more frequent surgical resections at ileal site, since approximately 52% of patients positive for the 1007finsC mutation had ileal surgery compared to about 17% of patients negative for the 1007finsC mutation. The association of ileal resections with mutations in the NOD2/CARD15 gene has been reported by other studies and by our own observation in a large German cohort.

In contrast to the frameshift mutation 1007finsC, we were not able to detect any association with all clinical parameters tested for the other two common missense mutations Arg702Trp and Gly908Arg. Most of the studies performed so far have not discriminated between the individual impact of the three NOD2/CARD15 mutations on the clinical phenotype. Since the frameshift mutation could lead to a truncated NOD2/CARD15 protein, it is likely to be functionally more important than the other two mutations. This hypothesis is supported by recent functional studies by Bonen et al., who demonstrated that this frameshift mutation had a complete defect in response to bacterial components such as peptidoglycan (PGN), whereas Arg702Trp and Gly908Arg showed intermediate responses.

Furthermore, the 1007finsC mutation was negatively correlated to the inflammatory subtype (if neither strictures nor fistulae were present) of Crohn’s disease. This has also been observed in another German Crohn’s disease population. There was a trend towards an association of the 1007finsC mutation with ileal involvement (1007finsC positive: 66.7%, 1007finsC negative: 51.2%), but it did not reach any statistical significance. Mutation within the NOD2/CARD15 gene and its association with ileal involvement have been reported by other investigators. Apart from ileal involvement, investigators have also described a younger age at onset of the disease in patients homozygous or compound heterozygous for NOD2/CARD15 mutations, whereas our study and others failed to notice this phenomenon.

In our analysis, we observed higher frequencies of all the three investigated NOD2/CARD15 mutations in Crohn’s disease patients compared to controls, which was in agreement with previous findings. With respect to the Gly908Arg mutation, this difference did not reach any statistical significance (P = 0.10). The lack of significance has also been reported by other studies, but that could also be due to the low allele frequency and a smaller sample size in our study. Among the 10 patients from the Roma (Gipsy) minority, we only detected one NOD2/CARD15 mutation (1007finsC). As mentioned above, a lower incidence of IBD in the Roma population from Hungary was described. Lower health consciousness, lower hygienic levels or a different genetic background among the Roma minority are some of the factors that could explain this phenomenon.

Interestingly, the so called Musician Gypsies (because they live a westernised life) appear to have a similar incidence of inflammatory bowel disease as the general population. However, since the sample size of Roma patients in our study was small, it could not be determined whether NOD2/CARD15 mutations or any other genetic alteration contributed to the lower incidence of Crohn’s disease in the Roma (Gipsy) minority.

In summary, NOD2/CARD15 mutations can be found in similar frequencies in Crohn’s disease patients from Hungary compared to western European populations in whom only the 1007finsC mutation within NOD2/CARD15 can predict an aggressive phenotype with stenotic disease behaviour and frequent ileal resections.

**ACKNOWLEDGEMENTS**

We thank all patients who were involved in this evaluation.

**REFERENCES**

1. Ogura Y, Bonen DK, Inohara N, Nicolea DL, Chen FF, Ramos R, Britton H, Moran T, Karaliukas R, Duerr RH, Achkar JP, Brant SR, Bayless TM, Kirschner BS, Hanauer SB, Nunez G, Cho JH. A frameshift mutation in NOD2 associated with susceptibility to Crohn’s disease. *Nature* 2001; 411: 603-606

2. Hugot JP, Chamaillard M, Zouali H, Lesage S, Cezard JP, Belaiche J, Almer S, Tysk C, O’Morain CA, Gassull M, Binder V, Finkel Y, Cortot A, Modigliani R, Laurent-Puig P, Gower-Rousseau C, Macry J, Colombel JF, Sahibatou M, Thomas G. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn’s disease. *Nature* 2001; 411: 599-603

3. Hampe J, Cuthbert A, Croucher PJ, Mirza MM, Mascheretti S, Fisher S, Frenzel H, King K, Hasselmeyer A, MacPherson AJ, Bridger S, van Deventer S, Forbes A, Nikolaus S, Lennard-Jones JE, Foelsch UR, Krawczak M, Lewis C, Schreiber S, Mathew CG. Association between insertion mutation in NOD2 gene and Crohn’s disease in German and British populations. *Lancet* 2001; 357: 1925-1927

4. Bonen DK, Cho JH. The genetics of inflammatory bowel disease. *Gastroenterology* 2003; 124: 521-536

5. Helio T, Halme L, Lappalainen M, Fodstad H, Paavola-Sakki P, Turunen U, Farkkila M, Krusiis T, Kontula K. CARD15 NOD2 gene variants are associated with familial occurring and complicated forms of Crohn’s disease. *Gut* 2003; 52: 558-562

6. Inoue N, Tamura K, Kinosuchi Y, Fukuda Y, Takahashi S, Ogura Y, Inohara N, Nunez G, Kishiy Y, Koike Y, Shimosegawa T, Shimoyama T, Hibi T. Lack of common NOD2 variants contribute to Japanese patients with crohn’s disease. *Gastroenterology* 2002; 123: 86-91

7. Leong RW, Armuzzi A, Ahmad T, Wong ML, Tse P, Jewell DP, Sung JY. NOD2/CARD15 gene polymorphisms and Crohn’s disease in the Chinese population. *Aliment Pharmacol Ther* 2003; 17: 1465-1470

8. Lakatos L, Mester G, Erdelyi Z, Balogh M, Szipo cs I, Kamaras G, Lakatos PL. Striking elevation in incidence and prevalence of inflammatory bowel disease in a province of western Hungary between 1977-2001. *World J Gastroenterol* 2004; 10: 404-409

9. Shivananda S, Lennard-Jones J, Logan R, Fear N, Price A, Carpenter L, van Blankenstein M. Incidence of inflammatory bowel disease across Europe: is there a difference between north and south? Results of the European Collaborative Study on Inflammatory Bowel Disease (EC-IBD). *Gut* 1996; 39: 690-697

10. Karlinger K, Gyorke T, Mester G, Mester A, Tarjan Z. The epidemiology and the pathogenesis of inflammatory bowel disease. *Eur J Radiol* 2000; 35: 154-167

11. Gasche C, Scholerich J, Brynskov J, D’Haens G, Hanauer SB,
Irvine EJ, Jewell DP, Sachar DB, Sandborn WJ, Sutherland LR. A simple classification of Crohn’s disease: report of the Working Party for the World Congresses of Gastroenterology, Vienna 1998. *Inflamm Bowel Dis* 2000; 6: 8-15

Ahmad T, Armuzzi A, Bunce M, Mulcahy-Hawes K, Marshall SE, Orchard TR, Crawshaw J, Large O, de Silva A, Cook JT, Barnardo M, Cullen S, Welsh KL, Jewell DP. The molecular classification of the clinical manifestations of Crohn’s disease. *Gastroenterology* 2002; 122: 854-866

Vermeire S, Wild G, Kocher K, Cousineau J, Dufresne L, Bitton A, Langelier D, Pare P, Lapointe G, Cohen A, Daly MJ, Rioux JD. CARD15 genetic variation in a Quebec population: prevalence, genotype-phenotype relationship, and haplotype structure. *Am J Hum Genet* 2002; 71: 74-83

Cuthbert AP, Fisher SA, Mirza MM, King K, Hampe J, Croucher PJ, Mascheretti S, Sanderson J, Forbes A, Mansfield J, Schreiber S, Lewis CM, Mathew CG. The contribution of NOD2 gene mutations to the risk and site of disease in inflammatory bowel disease. *Gastroenterology* 2002; 122: 867-874

Hampe J, Grebe J, Nikolaus S, Solberg C, Croucher PJ, Mascheretti S, Jahnsen J, Moum B, Klump B, Krawczak M, Mirza MM, Foelsch UR, Vatn M, Schreiber S. Association of NOD2 (CARD 15) genotype with clinical course of Crohn’s disease: a cohort study. *Lancet* 2002; 359: 1661-1665

16 Lesage S, Zouali H, Cezeard JP, Colombel JF, Belaiche J, Almer S, Tysk C, O’Morain C, Gassull M, Binder V, Finkel Y, Modigliani R, Gower-Rousseau C, Macry J, Merlin F, Chamaillard M, Jannot AS, Thomas G, Hugot JP. CARD15/NOD2 mutational analysis and genotype-phenotype correlation in 612 patients with inflammatory bowel disease. *Am J Hum Genet* 2002; 70: 845-857

17 Radlmayr M, Torok HP, Martin K, Folwaczny C. The c-insertion mutation of the NOD2 gene is associated with fistulizing and fibrostenotic phenotypes in Crohn’s disease. *Gastroenterology* 2002; 122: 2091-2092

18 Abreu MT, Taylor KD, Lin YC, Hang T, Gaiennie J, Landers CJ, Vasiliauskas EA, Kam LY, Rojany M, Papadakis KA, Rotter JI, Targan SR, Yang H. Mutations in NOD2 are associated with fibrostenosing disease in patients with Crohn’s disease. *Gastroenterology* 2002; 123: 679-688

19 Büning C, Genschel J, Bühner S, Krüger S, Kling K, Dignass A, Baier P, Bochow B, Ockenga J, Schmidt HH, Lochs H. Mutations in the NOD2/CARD15 gene in Crohn’s disease are associated with ileocecal resection and are a risk factor for reoperation. *Aliment Pharmacol Ther* 2004; 19: 1073-1079

20 Malchow H, Ewe K, Brandes JW, Goebell H, Ehms H, Sommer H, Jedsinsky H. European Cooperative Crohn’s Disease Study (ECCDS): results of drug treatment. *Gastroenterology* 1984; 86: 249-266

21 Bonen DK, Ogura Y, Nicolae DL, Inohara N, Saab L, Tanabe T, Chen FF, Foster SJ, Duerr RH, Brant SR, Cho JH, Nunez G. Crohn’s disease-associated NOD2 variants share a signaling defect in response to lipopolysaccharide and peptidoglycan. *Gastroenterology* 2003; 124: 140-146

22 Murillo L, Crusius JB, van Bodegraven AA, Alizadeh BZ, Pena AS. CARD15 gene and the classification of Crohn’s disease. *Immunogenetics* 2002; 54: 59-61

23 Sugimura K, Taylor KD, Lin YC, Hang T, Wang D, Tang YM, Fischel-Ghodsian N, Targan SR, Rotter JI, Yang H. A novel NOD2/CARD15 haplotype conferring risk for Crohn’s disease in Ashkenazi Jews. *Am J Hum Genet* 2003; 72: 509-518

Edited by Wang XL